Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global adeno-associated virus vector-based gene therapy market is expected to grow at a CAGR of 32.93% during the forecast period of 2024-2032, driven by focus on technological advancements in healthcare across the globe.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Adeno-associated virus (AAV) vector-based gene therapy is an approach in the field of medical genetics, principally known for its safety profile and efficacy in delivering genetic material into host cells. AAV vectors are derived from a small, naturally occurring virus that is not known to cause disease in humans, which makes them an attractive tool for gene therapy.
Increasing Collaborations and Partnerships to Affect the Market Landscape Significantly
In June 2023, Albumedix entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´s proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing. This collaboration aims to leverage Albumedix’s expertise in recombinant human albumin to improve the production processes for these vectors. The collaboration will include activities at both the CGT Catapult facility in Braintree and Albumedix's R&D center, focusing on process optimization, characterization, and formulation development of advanced therapies.
Surge in Development of New Products to Meet Rising Adeno-Associated Virus Vector-Based Gene Therapy Market Demand
In August 2023, Quest Diagnostics was granted breakthrough device designation from the United States Food and Drug Administration (FDA) for its AAVrh74 ELISA assay (CDx). The AAVrh74 ELISA assay is an enzyme-linked immunosorbent in vitro diagnostic assay used for the semi-quantitative detection of antibodies to AAVrh74 capsid in human serum. The designation is a process by the FDA aimed fast-tracking the development and review of medical devices and combination products that promise more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Global Adeno-Associated Virus Vector-Based Gene Therapy Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Trends | Impact |
Technological Advancements | Innovations in vector technology including capsid modification for reduced immunogenicity and improved tissue specificity, are expanding the therapeutic potential of AAV vectors. The increasing enhancements in vector design are important for increasing the precision of therapies to target specific tissues, thereby reducing off-target effects, and improving outcomes. Also, the advancements improve safety profile and expands the applicability to a broader range of diseases. |
Increasing Investments in Gene Therapy Companies | Pharmaceutical investments and venture capital is growing in gene therapy startups and major companies focuses on AAV vectors. This financial support not only boosts the scale of ongoing projects but also flourishes the emergence of innovative treatment modalities which has the potential to revolutionize the healthcare. |
Expansion into Chronic and Multifactorial Diseases | With the initial focus on monogenic diseases, AAV vector-based gene therapy is increasingly being explored for the treatment of multifactorial and chronic diseases like Alzheimer’s, Parkinson’s, and heart diseases. This strategic shift not only diversifies the applications of gene therapy but also has the potential to impact a larger patient population, significantly broadening the market. |
Growing Regulatory Support | The regulatory agencies like the FDA and EMA, are crucial in reducing the time for new treatments to arrive in the market. They are also vital in streamlining the process of approval for gene therapies. Special designations such as 'orphan drug' status and 'fast track' approvals are increasingly granted to AAV-based therapies, particularly those targeting rare and life-threatening diseases. Potentially leading to a surge in innovative treatments for complex diseases. |
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Therapeutic Application
Market Breakup by Target Disease
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Application Areas is Anticipated to Witness Substantial Growth
Based on therapeutic application, the market segmentation includes neurological disorders, ophthalmic disorders, muscular disorders, hematological disorders, and metabolic disorders. The neurological disorders have seen significant growth which can be attributed to an increasing prevalence of neurological diseases like Alzheimer’s and Parkinson’s, where AAV vector show promise in transporting genetic material directly to the brain. With the progress in research and clinical trials, the potential for treating complex diseases is expanding, thereby providing the market with significant growth.
For targeting retinal cells, AAV vectors are suitable and makes then ideal in treating inherited retinal diseases. Innovations in vector engineering and delivery techniques are considered to improve safety and efficacy of treatment, propelling significant market growth in the ophthalmic sector.
Rare Disease Target is Expected to Lead the Market Share
Based on target disease, the market constitutes rare diseases, cancer, and inherited genetic disorders. Rare disease segment benefits from regulatory support as orphan drug designations that provide benefit like market exclusivity and tax incentives. The emphasis on rare diseases, which often have limited effective treatment options fuels a significant part of research and development in AAV vector gene therapy. With advancements in target and vector optimization the potential to develop curative therapies is high.
The use of AAV vector in oncology to transport the tumor suppressor genes or suicide genes into cancer cells is growing. With the rising incidence of cancer worldwide along with limitations of current therapies in terms of side effects and specificity, there is strong investment and research in this domain. As AAV-based therapies for cancer advance through clinical trials and receive approvals, this segment is poised for rapid growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is dominating the regional landscape, owing to the advantage of having advanced biotechnological technologies, substantial healthcare expenditure and supportive regulatory policies. The presence of major pharmaceutical companies and several ongoing clinical trials are anticipated to drive the market’s growth.
Europe is expected to witness significant growth. It is fueled by strong government collaboration and funding between private and public sectors in research. Strong regulatory framework and high standards for patient care enables rapid adoption of advanced therapies such as gene therapies.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapeutic Application |
|
Breakup by Target Disease |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Adeno-Associated Virus Vector-Based Gene Therapy Market Size
Adeno-Associated Virus Vector-Based Gene Therapy Market Growth
Adeno-Associated Virus Vector-Based Gene Therapy Market Trends
Adeno-Associated Virus Vector-Based Gene Therapy Market Share
Adeno-Associated Virus Vector-Based Gene Therapy Market Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124